文献速递肝病消化道肿瘤与早癌

Setdb1 抑制肝细胞癌抗肿瘤免疫及三级淋巴结构形成

Setdb1 represses antitumor immunity and tertiary lymphoid structures in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2026-07-16

该研究在多种肝细胞癌(HCC)模型中敲除 Setdb1,发现 Setdb1 缺失可诱导三级淋巴结构(TLS)形成。机制上,Setdb1 缺失产生胞质 DNA 并激活 cGAS 通路,上调 Cxcl12 和 Zbp1,分别促进 B 细胞募集成熟和恶性细胞坏死性凋亡,从而促进 TLS 形成。临床样本中低 SETDB1 表达与较高 TLS 水平相关,提示 Setdb1 可能作为增强 HCC 免疫治疗效果的靶点。

要点

  • 低 SETDB1 表达与 HCC 临床样本中较高 TLS 水平相关。
  • Setdb1 缺失通过 cGAS/CXCL12 通路促进 B 细胞募集与成熟。
  • Setdb1 缺失诱导 Zbp1 介导的坏死性凋亡及内源性逆转录病毒表达,促进 TLS 形成。

核心结论

  • Setdb1 在 HCC 中抑制 TLS 形成,其缺失可诱导 TLS 形成并可能增强免疫治疗效果。

研究设计与样本

  • 在 Akt/NRAS 和 Myc/CTNNB1 流体动力学模型及 Hepa1-6 原位和皮下肿瘤模型等多种 HCC 模型中敲除 Setdb1。
  • 使用空间转录组学和多色染色验证 TLS 形成,并用实时逆转录 PCR 和蛋白质印迹进行机制研究。

主要发现

  • 临床样本中低 SETDB1 表达与较高 TLS 水平相关。
  • Setdb1 缺失在多种 HCC 模型中诱导 TLS 形成。
  • Setdb1 缺失产生胞质 DNA 并激活 cGAS 通路,增加 Cxcl12 和 Zbp1 表达。
  • Cxcl12 在肝细胞和癌细胞中上调,促进 B 细胞募集和成熟;Zbp1 在恶性细胞中激活并诱导坏死性凋亡,促进 TLS 形成。
  • Setdb1 缺失还增加内源性逆转录病毒表达,可能作为新抗原促进 B 细胞成熟。

临床怎么用

  • SETDB1 抑制可能作为与免疫治疗联合的策略用于 HCC 治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tertiary lymphoid structures (TLSs) are ectopic lymphoid structures that develop in peripheral tissues in response to chronic inflammation or tumors. TLS maturation is associated with improved responses to tumor immunotherapy. However, the underlying mechanisms of TLS formation remain elusive. Here, we investigated the role of SETDB1 in TLS formation in hepatocellular carcinoma (HCC). METHODS: Setdb1 was knocked out in multiple HCC models, including Akt/NRAS and Myc/CTNNB1 hydrodynamic models and Hepa1-6 orthotopic and subcutaneous tumor models. Spatial transcriptomics and multiplex staining were used to verify TLS formation. Real-time reverse-transcription PCR and western blotting were used for mechanistic investigations. RESULTS: Low SETDB1 expression was associated with higher TLS levels in clinical samples, and Setdb1 depletion induced TLS formation in multiple HCC models. Setdb1 depletion generated cytosolic DNA and activated the cGAS pathway, which increased Cxcl12 and Zbp1 expression. Cxcl12 was upregulated in hepatocytes and cancer cells and contributed to the recruitment and maturation of B cells. Zbp1 was activated in malignant cells and induced necroptosis, contributing to TLS formation. Setdb1 depletion also increased the expression of endogenous retroviruses, which may act as neoantigens and promote B-cell maturation. CONCLUSIONS: Our study has revealed a critical role for Setdb1 in TLS formation and suggests a potential role for Setdb1 as a therapeutic target to enhance the effects of immunotherapy in HCC. IMPACT AND IMPLICATIONS: The current study found that Setdb1 depletion induces the formation of tertiary lymphoid structures (TLSs) in hepatocellular carcinoma (HCC). TLSs are ectopic lymphoid structures that develop in peripheral tissues in response to chronic inflammation or tumors. Mature TLSs are associated with improved responses to tumor immunotherapy. This study uncovers a new cGAS/CXCL12 pathway involved in TLS formation, providing insights into the mechanisms regulating antitumor immunity. It also provides a potential strategy for combining SETDB1 inhibition with immunotherapy for HCC treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Shen SJ, Zhou K, Wang CY, et al. Setdb1 represses antitumor immunity and tertiary lymphoid structures in hepatocellular carcinoma. J Hepatol. 2026. PMID: 42457040. doi:10.1016/j.jhep.2026.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。